yabbycasinofreespins| Concino Biotech rose more than 9% against the market. Vaccine stocks once again attracted attention. The company has abundant research pipelines

Concino Biotech (06185) rose 9.5 percent against the market in early tradingyabbycasinofreespins.37%, currently reported at 23yabbycasinofreespins.35 Hong Kong dollars, with a turnover of 56.5263 million Hong Kong dollars.

It is reported that in terms of pipeline development, the marketing application for Concino Biotech's 13-valent pneumonia conjugate vaccine PCV13i has been accepted.yabbycasinofreespins; The infant component DPT DTcP has completed Phase III enrollment of subjects; the adsorbed tetanus vaccine has started Phase III clinical trials; the recombinant herpes zoster vaccine (adenovirus vector) has started Phase I clinical trials in Canada; and the recombinant polio vaccine has started Phase I clinical trials in Australia. In addition, the company and AstraZeneca reached an agreement on the development of mRNA vaccines.yabbycasinofreespinsCooperation development agreement.